{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-025388","form_type":"8-K","ticker":"JNJ","cik":"0000200406","company_name":"JOHNSON & JOHNSON","filed_at":"2023-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.178357+00:00","generated_at":"2026-06-13T04:34:09.022530+00:00","sec_items":["8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"JNJ Q2 preliminary: sales $25.53B (+6.3%), EPS $1.96 (+8.9%)","bullets":["Net earnings $5.14B vs $4.81B; diluted EPS $1.96 vs $1.80 YoY.","MedTech sales $7.79B (+12.9%) driven by Abiomed and Electrophysiology growth.","Pharmaceutical sales $13.73B (+3.1%); DARZALEX +22.4%, TREMFYA +18.3%, CARVYKTI $117M.","Consumer Health sales $4.01B (+5.4%); OTC +12.0%, Skin Health/Beauty +2.0%.","Preliminary results subject to adjustment; six-month net earnings fell 49.1% due to $7.2B other expense (Kenvue)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-025388","json":"https://secwatch.observer/filing/0001628280-23-025388.json","markdown":"https://secwatch.observer/filing/0001628280-23-025388.md","text":"https://secwatch.observer/filing/0001628280-23-025388.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/200406/000162828023025388/0001628280-23-025388-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/200406/000162828023025388/jnj-20230724.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T04:34:09.022530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}